USFDA nod to Zydus Lifesciences Famotidine Injection

Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed.

Published On 2022-11-23 10:46 GMT   |   Update On 2022-11-23 10:46 GMT
Advertisement

Ahmedabad: Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Famotidine Injection USP, 40 mg/4 mL (10 mg/mL) and 200 mg/20 mL (10 mg/mL) multiple-dose vials (USRLD: Pepcid injection).

Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. This medication is also used to treat certain stomach and throat (esophagus) problems such as erosive esophagitis, gastroesophageal reflux disease-GERD, and Zollinger-Ellison syndrome.

Advertisement

Read also: Zydus Lifesciences Chief Pankaj R Patel appointed as new Chairperson of IIM Ahmedabad Board of Governors

Famotidine Injection had annual sales of USD 1.9 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022). The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.

The group now has 333 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus Lifesciences Chief Pankaj R Patel appointed as new Chairperson of IIM Ahmedabad Board of Governors

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the manufacture of generic drugs. Zydus group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim in India and in the US and Brazil.

Read also: Zydus Lifesciences bags USFDA nod for Bisoprolol Fumarate, Hydrochlorothiazide Tablets

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News